Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jun;104(6):e240-e243.
doi: 10.3324/haematol.2018.209460. Epub 2019 Jan 10.

FLT3 ligand plasma levels in acute myeloid leukemia

Pierre Peterlin  1   2 , Joelle Gaschet  2 , Thierry Guillaume  3   2 , Alice Garnier  3 , Marion Eveillard  2   4 , Amandine Le Bourgeois  3 , Michel Cherel  2   5 , Camille Debord  4 , Yannick Le Bris  2   4 , Olivier Theisen  4 , Béatrice Mahé  3 , Viviane Dubruille  3 , Catherine Godon  4 , Nelly Robillard  4 , Soraya Wuilleme  4 , Cyrille Touzeau  3 , Thomas Gastinne  3 , Nicolas Blin  3 , Anne Lok  3 , Antoine Bonnet  3 , Steven Le Gouill  3   2 , Philippe Moreau  3   2 , Marie-C Béné  2   4 , Patrice Chevallier  3   2
Affiliations

FLT3 ligand plasma levels in acute myeloid leukemia

Pierre Peterlin et al. Haematologica. 2019 Jun.
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Three different kinetic profiles of soluble FLT3 ligand concentrations during induction treatment in patients with acute myeloid leukemia. FLI: sustained increase of soluble FLT3 ligand concentrations (sFLc) from day 1 to day 22 of induction (n=26). FLD: an increase of sFLc between days 1 and 15, followed by a decrease until day 22 of induction (n=22). FLL: stable, low sFLc (<1000 pg/mL) between day 1 and day 22 of induction (n=14). X axis: 1 = day 1; 2 = day 8; 3 = day 15; 4 = day 22.
Figure 2.
Figure 2.
Progression-free and overall survival rates according to the three kinetic profiles of soluble FLT3 ligand concentrations during induction treatment in patients with acute myeloid leukemia. PFS: progression-free survival; OS: overall survival; FLI: sustained increase of soluble FLT3 ligand concentrations (sFLc) from day 1 to day 22 of induction; FLD: an increase of sFLc between days 1 and 15, followed by a decrease until day 22 of induction; FLL: stable, low sFLc throughout induction.
See this image and copyright information in PMC

References

    1. Tsapogas P, Mooney CJ, Brown G, Rolink A. The cytokine Flt3-ligand in normal and malignant hematopoiesis. Int J Mol Sci. 2017;18(6).pii:E1115. - PMC - PubMed
    1. Bertho JM, Demarquay C, Frick J, et al. Level of Flt3-ligand in plasma: a possible new bio-indicator for radiation-induced aplasia. Int J Radiat Biol. 2001;77(6):703–712. - PubMed
    1. Prat M, Frick J, Laporte J-P, Thierry D, Gorin N-C, Bertho J-M. Kinetics of plasma FLT3 ligand concentration in hematopoietic stem cell transplanted patients. Leuk Lymphoma. 2006;47(1):77–80. - PubMed
    1. Haidar JH, Bazarbachi A, Mahfouz R, Haidar HA, Jaafar H, Daher R. Serum Flt3 ligand variation as a predictive indicator of hematopoietic stem cell mobilization. J Hematother Stem Cell Res. 2002;11(3):533–538. - PubMed
    1. Meierhoff G, Dehmel U, Gruss HJ, et al. Expression of FLT3 receptor and FLT3-ligand in human leukemia-lymphoma cell lines. Leukemia. 1995;9(8):1368–1372. - PubMed

Publication types